glp 1 and heart failure GLP-1 receptor agonist-based therapies cardiovascular risk: a review of mechanisms Frontiers | The potential of

Yi, a bariatric surgeon, cuts through the noise on GLP-1 medications for men

Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024

Pharmacist-led support for provider-directed care.

In adipose tissue, GIPR promotes lipid storage and reduces lipolysis, contributing to energy balance

This review aims to summarize current scientific evidence on the pharmacogenetics of the GLP-1 RA /liraglutide/ and the possible implementation in the treatment of T2D.

Objective To assess whether use of glucagon-like peptide-1 (GLP-1) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors